US Earnings Financial Results SEC Filings — June 16, 2026

16-06-2026

QuasarEdge Acquisition Corp completed its initial public offering (IPO) during the quarter, raising $115.0M in gross proceeds and $2.85M from a private placement, resulting in total assets of $116.8M as of April 30, 2026 (up from $0.4M at January 31, 2026). The company reported net income of $79,108 for the three months ended April 30, 2026, driven by $151,407 in interest earned on trust investments, though it incurred $72,299 in formation and operating costs. Cash held in the trust account stood at $115.7M, while cash on hand increased to $810,746 from just $1,248 at the start of the period.

• · The company issued 11,500,000 ordinary shares subject to possible redemption at a redemption value of $10.06 per share, totaling $115.7M.
• · Non-redeemable ordinary shares outstanding increased from 4,025,000 to 4,540,000 during the quarter.
• · The company incurred $72,299 in formation and operating costs and had no business combination expenses.
• · Net cash used in operating activities was $34,220, while net cash generated from financing activities was $116.4M.
• · The company had a promissory note – related party of $465,000 at January 31, 2026, which was fully repaid by April 30, 2026.
• · A remeasurement of ordinary shares subject to possible redemption reduced additional paid-in capital by $6.0M.

16-06-2026

Kaival Brands Innovations Group, Inc. reported a net loss of $574,544 for Q2 FY2026 (three months ended April 30, 2026), a significant improvement from a net loss of $1,997,653 in the same quarter last year. Total revenues declined 20.2% to $37,530 from $47,045, driven by lower royalty revenue. The company's cash position dropped to $277,951 from $534,406 at the start of the fiscal year, and stockholders' equity turned negative at ($20,662) compared to $99,967 at October 31, 2025.

• · General and administrative expenses decreased to $612,074 in Q2 FY2026 from $1,331,183 in Q2 FY2025, a 54% reduction.
• · Stock-based compensation was $24,320 in H1 FY2026 versus $2,873,750 in H1 FY2025, a 99% decrease.
• · The company had no revenues from product sales in Q2 FY2026 or H1 FY2026, compared to $4,073 and $46,755 respectively in the prior year periods.
• · Net cash used in operating activities improved to $1,171,898 in H1 FY2026 from $1,483,982 in H1 FY2025.
• · The company raised $1,015,443 through issuance of common stock in H1 FY2026.
• · As of April 30, 2026, the company had an accumulated deficit of $55,288,446.
• · The company faces significant risks including reliance on Bidi Vapor, patent infringement claims by R.J. Reynolds, and FDA marketing denial orders for Bidi Stick products.

16-06-2026

Terra Innovatum Global N.V. (NKLR) reported a net income of $539.5M for FY2025, a dramatic turnaround from a net loss of $34K in FY2024, driven primarily by a $560.0M non-cash gain from the change in fair value of a share-settled contingent liability. However, the company has generated no revenue since inception and operating losses surged to $33.7M from $153K, while total shareholders' deficit widened to $(93.6M) from $(32K).

• · The company has incurred losses and generated no revenue since inception, and expects to continue incurring losses for the foreseeable future.
• · General and administrative expenses surged to $32.3M in FY2025 from $78K in FY2024, a 41,324% increase.
• · Development costs increased to $1.4M from $75K, a 1,751% increase.
• · Other income, net was $573.2M in FY2025, primarily from a $560.0M change in fair value of share-settled contingent liability and $16.6M from warrant liabilities.
• · Interest expense was $1.4M in FY2025, compared to $0 in FY2024.
• · Other expense, net was $1.9M in FY2025, compared to $0 in FY2024.
• · Net cash used in operating activities was $10.3M in FY2025, up from $42K in FY2024.
• · Financing activities provided $112.3M in FY2025, up from $112K in FY2024.
• · Total shareholders' deficit worsened to $(93.6M) from $(32K), driven by an accumulated deficit of $(607.3M).
• · The company had a foreign currency translation loss of $(10.1M) in FY2025, compared to a gain of $1K in FY2024.
• · Net income per share (basic and diluted) was $9.74 for FY2025, compared to $0.00 for FY2024.
• · The company changed its name from Terra Innovatum Global Srl. to Terra Innovatum Global N.V.

16-06-2026

Aimei Health Technology Co., Ltd. filed its 10-Q for the quarter ended March 31, 2026, reporting net income of $45,440, a 75.4% decline from $184,662 in the prior year period. The decrease was driven by lower interest income on trust assets ($107,424 vs $598,076), partially offset by a significant reduction in general and administrative costs ($61,984 vs $413,414). The SPAC continues to seek a business combination, with redeemable shares outstanding falling to 1,040,332 from 5,157,440 due to redemptions.

• · Total assets increased slightly from $12,103,039 at Dec 31, 2025 to $12,294,903 at March 31, 2026, driven by higher cash held in trust ($12,100,110 to $12,276,196).
• · Net cash used in operating activities improved to -$74,613 from -$224,009 in prior year period.
• · Redeemable ordinary shares outstanding decreased by about 80% from prior year, indicating significant redemptions.
• · The company had extension loans from a related party of $2,092,724 at March 31, 2026, up from $2,024,062 at year-end 2025.
• · Shareholders' deficit worsened from $4,058,731 to $4,189,377 due to extension costs and remeasurement of redeemable shares.

16-06-2026

Sonoma Pharmaceuticals, Inc. reported a decrease in net loss from $3.5M in FY2025 to $3.2M in FY2026, driven by a 33% revenue increase that outpaced cost growth. However, gross margin remained flat at 38%, while selling, general and administrative expenses grew only 3% but still consumed 39% of revenue. The company continues to face competitive pressures and reliance on successful sales and marketing to drive adoption.

• · Cost of revenues increased 37% YoY to $12.1M, matching the gross margin percentage unchanged at 38%.
• · R&D spending rose 25% to $2.3M, while SG&A rose only 3% to $7.6M.
• · Net loss per share improved from $(2.79) to $(1.89), partly due to a 36% increase in weighted-average shares outstanding (1,684K vs 1,241K).
• · The filing highlights risks including foreign exchange fluctuations, trade restrictions, and reliance on sales and marketing effectiveness.
• · No specific revenue figure is provided in the extracted data; revenue can be inferred as gross profit plus cost of revenues = $19.5M for FY2026 and $14.3M for FY2025.

16-06-2026

Vynleads, Inc. reported no revenue for Q1 2026 and Q1 2025, with net loss widening 19.7% to $96,956 from $80,970 year-over-year. Cash declined sharply to $262 from $44,628 at year-end 2025, while total liabilities increased to $421,730 and stockholders' deficit deepened to ($416,887). The company continues to rely on in-kind service contributions and has no operating cash inflows.

• · Gross loss improved to ($2,028) in Q1 2026 from ($4,718) in Q1 2025, a 57.0% reduction.
• · Accounts payable and accrued expenses increased to $256,395 from $240,818 at year-end 2025.
• · Notes payable remained nearly flat at $165,335 vs $165,322.
• · Additional paid-in capital increased by $32,500 due to in-kind contribution of services.
• · No income taxes paid or interest paid in either period.
• · 100,000 stock options outstanding with a weighted average exercise price of $0.225 and weighted average contractual life of 2.21 years.
• · The company has a fee arrangement with CRG Finance AG for introductions to non-U.S. persons, with fees ranging from 1% to 7% of proceeds or consideration.

16-06-2026

Transuite.Org Inc. reported its first-ever revenue of $121,784 for the three months ended March 31, 2026, compared to $0 in the prior year period, generating a gross profit of $109,624. However, the net loss attributable to the company widened significantly to $3,196,465 from $486,247 in Q1 2025, driven by a surge in professional fees including $3,306,511 in stock-based compensation. Total stockholders' equity improved to $109,931 from a deficit of $(472,436) at year-end 2025, but the company continues to report an accumulated deficit of $(40,815,538) and remains a going concern.

• · Accounts receivable surged to $120,781 from $19,299 at year-end 2025, a 526% increase.
• · Prepaid expenses increased to $38,710 from $18,757, up 106%.
• · Stock payable decreased sharply to $169,997 from $688,934, a 75% decline.
• · Deferred compensation decreased to $6,375,609 from $9,857,820, a 35% reduction, reflecting stock-based compensation recognition.
• · The company issued 3,500,000 shares for the acquisition of Goldfinch Group Co. Ltd. HK valued at $350,000.
• · 3,000,000 shares were issued to SolanAI Global Ltd. as treasury stock valued at $600,000.
• · Net cash used in operating activities improved to $(5,483) from $(72,146) in Q1 2025.
• · The company had a loan payable of $40,692 as of March 31, 2026, compared to $0 at year-end 2025.
• · Non-controlling interest shifted to a deficit of $(44,648) from a positive $12,708 at year-end 2025.

16-06-2026

La-Z-Boy Incorporated reported fiscal 2026 sales of $2.127B, up 0.8% from $2.109B in fiscal 2025, with net income attributable to the company of $101.985M versus $99.556M, a 2.4% increase. However, operating income declined 4.9% to $129.207M and operating margin contracted from 6.4% to 6.1%, while cash and equivalents fell 7.7% to $303.213M.

• · Goodwill impairment was $19.967M in FY26 vs $20.581M in FY25.
• · Selling, general and administrative expense increased to $787.427M from $770.000M.
• · Interest income declined to $11.880M from $14.877M.
• · Income tax expense decreased to $35.894M from $46.182M.
• · Basic EPS was $2.49 in FY26 vs $2.39 in FY25; diluted EPS was $2.47 vs $2.35.
• · Net cash used for investing activities increased to $138.608M from $98.389M.
• · Net cash used for financing activities decreased to $91.146M from $102.612M.
• · Total current assets decreased to $773.914M from $805.688M.
• · Inventories, net decreased to $218.445M from $255.285M.
• · Goodwill increased to $243.300M from $205.590M.
• · Right of use lease assets increased to $520.726M from $452.848M.
• · Total current liabilities increased to $429.895M from $420.791M.
• · Retained earnings increased to $610.423M from $597.432M.
• · Accumulated other comprehensive loss improved to $(1.527)M from $(3.574)M.
• · Noncontrolling interests increased to $12.677M from $11.353M.

16-06-2026

DentonX Inc filed its 10-Q for the quarter ended March 31, 2026, reporting a net loss of $981,811 for the three-month period and $1,701,014 for the six-month period. Cash decreased sharply from $359,981 at September 30, 2025 to $29,756 at March 31, 2026, while total liabilities increased to $1,388,256 from $232,330, driven by a significant rise in due to related parties ($1,367,394). The company's stockholders' equity shifted from a positive $167,651 to a deficit of $1,340,000, reflecting ongoing operating losses and reliance on related-party financing.

• · The company had no revenue for the periods reported; all expenses are operating expenses.
• · Legal and professional services expense includes $859,560 for the three months and $1,418,659 for the six months in fees incurred with related parties.
• · Basic and diluted net loss per share was $(0.05) for the three months and $(0.11) for the six months ended March 31, 2026.
• · The company issued 2,599,273 shares of common stock for services received during the six months ended March 31, 2026.
• · The company issued 6,400,000 shares of common stock against advances during the six months ended March 31, 2026.
• · Net cash used in operating activities was $340,885 for the six months ended March 31, 2026.
• · The company had no comparable prior period data for the six months ended March 31, 2025 (all zeros).
• · The SAFE liability of $11,683 represents an unrealized loss of $1,683 for both the three and six month periods.
• · Total non-cash transactions for the six months ended March 31, 2026 were $192,703.

16-06-2026

Vince Holding Corp. reported net sales of $64.0M for Q1 FY26, up 10.5% from $57.9M in Q1 FY25, driven by improved performance. However, the company reported a net loss of $2.1M, an improvement from a net loss of $4.8M in the prior year, but still negative. Operating loss narrowed to $2.6M from $4.4M, while gross profit increased to $32.4M from $29.2M. Cash and cash equivalents rose to $0.8M from $0.5M at year-end, but long-term debt increased to $29.1M from $19.5M.

• · Gross margin improved to 50.6% from 50.3% year-over-year.
• · Selling, general and administrative expenses increased to $35.0M from $33.6M, up 4.3%.
• · Interest expense decreased to $0.6M from $0.9M.
• · Equity in net income of equity method investment was $0.7M vs $0.5M.
• · Net cash used in operating activities improved to $8.9M from $11.8M.
• · Capital expenditures decreased significantly to $0.2M from $1.4M.
• · Revolving Credit Facility borrowings increased to $20.1M from $10.7M.
• · Third Lien Credit Facility increased to $9.0M from $8.8M.
• · Accumulated deficit widened to $(1,112.4M) from $(1,110.3M).

16-06-2026

Stark Focus Group, Inc. reported a net loss of $3,726 for the three months ended March 31, 2026, compared to a net loss of $10,983 in the same period of 2025, representing a 66% improvement. The company has no revenue, zero cash, and total liabilities of $186,538 exceed total stockholders' deficit of $186,538, indicating a negative net worth. Operating cash flow improved to negative $2,500 from negative $7,300 year-over-year, but the company remains dependent on related-party financing.

• · Zero cash and cash equivalents at both March 31, 2026 and December 31, 2025.
• · Total liabilities increased 2% from $182,812 (Dec 31, 2025) to $186,538 (Mar 31, 2026).
• · Stockholders' deficit increased 2% from $182,812 (Dec 31, 2025) to $186,538 (Mar 31, 2026).
• · Accounts payable and accrued expenses decreased from $9,946 (Dec 31, 2025) to $8,796 (Mar 31, 2026).
• · Convertible note increased from $82,630 (Dec 31, 2025) to $87,120 (Mar 31, 2026).
• · No revenue generated in either period.
• · Basic and diluted earnings per share were $0.00 for both periods.
• · No cash paid for interest or income taxes in either period.

16-06-2026

Nobility Homes Inc reported a decline in financial performance for Q2 2026 and the first half of fiscal 2026. Net sales for Q2 2026 were $12.41M, down 15.9% from $14.76M in Q2 2025, and net income fell 23.2% to $1.76M from $2.29M. For the six-month period, net sales decreased 15.1% to $22.91M from $27.00M, while net income dropped 20.7% to $3.39M from $4.27M. The company maintained a strong balance sheet with $9.86M in cash and equivalents and total stockholders' equity of $56.52M, but total assets decreased 5.3% from $67.15M to $63.62M.

• · Dividend per share increased to $1.50 in Q2 2026 from $1.25 in Q2 2025, a 20% increase.
• · Cash and cash equivalents decreased 25.5% from $13.23M (Nov 1, 2025) to $9.86M (May 2, 2026).
• · Total assets decreased 5.3% from $67.15M to $63.62M.
• · Inventories increased 3.7% to $20.46M, driven by higher finished homes and pre-owned homes.
• · Operating cash flow improved 47.9% to $4.88M in H1 2026 from $3.30M in H1 2025.
• · Interest income decreased 27.1% in Q2 and 18.9% in H1 2026.
• · Selling, general and administrative expenses decreased 18.9% in Q2 and 18.6% in H1.
• · Stock-based compensation increased 43.1% to $115.6K in H1 2026.

16-06-2026

LAMY (LMMY) reported a net loss of $19,083 for the three months ended February 28, 2026, compared to net income of $80,129 in the same period last year, driven by a $62,108 negative gross profit and $174,897 in operating expenses. The company completed an acquisition of Exousia AI, recording a $22,050,000 intangible asset and a $217,922 gain on acquisition, while total assets surged to $22,050,670 from zero at May 31, 2025. However, the company had zero cash and cash equivalents at period end, and the accumulated deficit widened to $288,623 from $31,770.

• · The company issued 62,223,000 common shares in connection with the acquisition of Exousia AI, valued at $22,050,000.
• · Research and development expenses were $161,426 for the three and nine months ended February 28, 2026, compared to $0 in the prior periods.
• · Professional fees totaled $10,600 for the three months and $31,350 for the nine months ended February 28, 2026.
• · The company had $0 in cash and cash equivalents at both February 28, 2026 and May 31, 2025.
• · Net cash provided by operating activities was $176,626 for the nine months ended February 28, 2026, up from $86,538 in the prior period.
• · The company had an accumulated deficit of $288,623 as of February 28, 2026, compared to $31,770 as of May 31, 2025.
• · Weighted average shares outstanding increased from 7,777,000 to 16,764,767 for the three-month period and from 7,000,000 to 12,270,883 for the nine-month period.